俞德超押注创新药15年收获千亿市值 信达生物减肥药上市抢食国际巨头蛋糕

长江商报
30 Jun

创业15年,好消息接二连三地到来,俞德超向着国际生物制药巨头的目标一步步迈进。6月27日, 信达生物 (01801.HK)宣布,玛仕度肽注射液(商品名:信尔美)获得中国国家药品监督管理局(NMPA)批准上市。这是全球首个且唯一上市的GCG/GLP-1双受体激动减重降糖药物,将与诺和诺德的司美格鲁肽、 礼来 的替尔泊肽直接竞争。从放牛娃到科学家再到 创新药 领军人物,作为信达生物创始人,俞德超在业界...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10